Arcellx (ACLX) Cash & Current Investments (2021 - 2025)
Arcellx's (ACLX) quarterly Cash & Current Investments came in at $450.3 million in Q4 2025, down 23.33% year-on-year from $587.4 million in Q4 2024, and down 2.39% quarter-over-quarter from $461.4 million in Q3 2025.
Arcellx (ACLX) Cash & Current Investments (2021 - 2025) Analysis & Trends
Arcellx's Cash & Current Investments history runs 5 years deep, the most recent figure standing at $450.3 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments fell 23.33% year-over-year to $450.3 million in Q4 2025; TTM through Dec 2025 was $450.3 million, a 23.33% decrease from a year earlier, with the FY2025 full-year figure at $450.3 million, down 23.33% from the prior year.
- Cash & Current Investments slipped to $450.3 million in Q4 2025 per ACLX's latest filing, from $461.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $702.0 million in Q4 2023 and bottomed at $62.3 million in Q2 2025.
- The 5-year median for Cash & Current Investments is $245.9 million (2022), against an average of $300.1 million.
- Across the five-year window, Cash & Current Investments jumped 993.84% in 2023 and plunged 80.21% in 2024, its largest moves.
- Year by year, Cash & Current Investments stood at $104.6 million in 2021, then sank by 38.65% to $64.2 million in 2022, then soared by 993.84% to $702.0 million in 2023, then declined by 16.33% to $587.4 million in 2024, then retreated by 23.33% to $450.3 million in 2025.
- Per Business Quant, the three latest ACLX Cash & Current Investments figures stand at $450.3 million (Q4 2025), $461.4 million (Q3 2025), and $62.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 450.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 450.33 Mn |
| Sep 30, 2025 | 461.38 Mn |
| Jun 30, 2025 | 62.34 Mn |
| Mar 31, 2025 | 543.27 Mn |
| Dec 31, 2024 | 587.38 Mn |
| Sep 30, 2024 | 162.05 Mn |
| Jun 30, 2024 | 100.23 Mn |
| Mar 31, 2024 | 154.78 Mn |
| Dec 31, 2023 | 702.02 Mn |
| Sep 30, 2023 | 439.72 Mn |
| Jun 30, 2023 | 506.48 Mn |
| Mar 31, 2023 | 533.59 Mn |
| Dec 31, 2022 | 64.18 Mn |
| Sep 30, 2022 | 280.78 Mn |
| Jun 30, 2022 | 306.99 Mn |
| Mar 31, 2022 | 210.93 Mn |
| Dec 31, 2021 | 104.62 Mn |
| Sep 30, 2021 | 70.03 Mn |
| Jun 30, 2021 | 143.79 Mn |
| Mar 31, 2021 | 117.65 Mn |